ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Sees Significant Increase in Short Interest

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report) saw a significant increase in short interest in the month of October. As of October 30th, there was short interest totaling 9,470 shares, an increase of 66.4% from the October 15th total of 5,692 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average daily trading volume, of 28,464 shares, the short-interest ratio is currently 0.3 days.

Institutional Trading of ALPS Medical Breakthroughs ETF

Hedge funds and other institutional investors have recently modified their holdings of the business. Fig Financial Advisory Services Inc. ADV acquired a new position in ALPS Medical Breakthroughs ETF in the third quarter valued at $1,759,000. Bank of America Corp DE lifted its holdings in shares of ALPS Medical Breakthroughs ETF by 63.1% in the first quarter. Bank of America Corp DE now owns 98,679 shares of the company’s stock valued at $5,165,000 after purchasing an additional 38,193 shares in the last quarter. Kestra Advisory Services LLC lifted its position in shares of ALPS Medical Breakthroughs ETF by 27.6% in the first quarter. Kestra Advisory Services LLC now owns 8,186 shares of the company’s stock valued at $428,000 after acquiring an additional 1,772 shares in the last quarter. Independent Financial Group LLC acquired a new position in ALPS Medical Breakthroughs ETF in the 1st quarter valued at $283,000. Finally, Phoenix Wealth Advisors boosted its holdings in shares of ALPS Medical Breakthroughs ETF by 33.6% in the 3rd quarter. Phoenix Wealth Advisors now owns 11,212 shares of the company’s stock valued at $654,000 after purchasing an additional 2,822 shares during the last quarter.

ALPS Medical Breakthroughs ETF Stock Down 3.2%

Shares of SBIO traded down $1.76 during trading hours on Monday, reaching $53.87. 18,349 shares of the company traded hands, compared to its average volume of 37,176. The business has a fifty day moving average price of $57.31 and a 200-day moving average price of $57.19. ALPS Medical Breakthroughs ETF has a 12-month low of $45.65 and a 12-month high of $70.85. The stock has a market capitalization of $180.46 million, a P/E ratio of 6.73 and a beta of 0.79.

About ALPS Medical Breakthroughs ETF

(Get Free Report)

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.

Featured Articles

Receive News & Ratings for ALPS Medical Breakthroughs ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALPS Medical Breakthroughs ETF and related companies with MarketBeat.com's FREE daily email newsletter.